Change to Board

December 28, 2023, Vancouver, British Columbia: Gemina Laboratories Ltd. (CSE: GLAB)  (FRA:8I7) (the “Company” or “Gemina”) today announces that Dr. Rob Porter has stepped down  from the board and resigned as President. Dr. Porter will continue as Managing Director of  RAPIvD and will focus on its continued growth.  

Brian Firth, Gemina CEO, commented “On behalf of the board, I would like to thank Dr. Porter  for his contribution over the last 12 months. Gemina is now in a strong position to focus on  growth through its multiple channels to market.” 

On Behalf of the Board of Directors 

John Davies 

Chairman 

Gemina Laboratories Ltd. 

About Gemina Laboratories Ltd. 

Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Our technology drives testing platforms that are fast, affordable and accurate, and easily self-administered. Our development pipeline includes platforms for the rapid testing of COVID-19, influenza and other viruses. Additional information on the Company can be found at www.geminalabs.com. 

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is  defined in the policies of the Canadian Securities Exchange) accepts responsibility for the  adequacy or accuracy of this Release. 

Forward Looking Statements 

This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Such statements include statements regarding the anticipated terms of any proposed transaction or engagement. Information and statements which are not purely historical fact are forward-looking statements. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, 

performance, and achievements expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Furthermore, the Company is presently unable to fully quantify the impact that the Covid-19 pandemic will have on its operations and recognizes that certain eventualities may affect planned or assumed performance moving forward. As such, any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes  no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws. 

For more information regarding the Company, please contact: 

Glen Axelrod 

Bristol Capital Limited 

Telephone: 905 326 1888 

Email: investor@geminalabs.com